Evidence map›Paper›PMID 33508690›Full record

Trial reportDrug and alcohol dependence2021

Within-subject evaluation of interim buprenorphine treatment during waitlist delays.

Tatum N Oleskowicz, Taylor A Ochalek, Kelly R Peck, Gary J Badger, Stacey C Sigmon

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tatum N OleskowiczVermont Center on Behavior and Health, University of Vermont, 1 S. Prospect St., Burlington, VT, 05401, USA; Department of Psychological Science, University of Vermont, 2 Colchester Ave., Burlington, VT, 05401, USA.
Taylor A OchalekVermont Center on Behavior and Health, University of Vermont, 1 S. Prospect St., Burlington, VT, 05401, USA; Department of Psychological Science, University of Vermont, 2 Colchester Ave., Burlington, VT, 05401, USA.
Kelly R PeckVermont Center on Behavior and Health, University of Vermont, 1 S. Prospect St., Burlington, VT, 05401, USA; Department of Psychological Science, University of Vermont, 2 Colchester Ave., Burlington, VT, 05401, USA; Department of Psychiatry, University of Vermont, 1 S. Prospect St., Burlington, VT, 05401, USA.
Gary J BadgerVermont Center on Behavior and Health, University of Vermont, 1 S. Prospect St., Burlington, VT, 05401, USA; Department of Medical Biostatistics, University of Vermont, 27 Hills Building, Burlington, VT, 05401, USA.
Stacey C SigmonVermont Center on Behavior and Health, University of Vermont, 1 S. Prospect St., Burlington, VT, 05401, USA; Department of Psychological Science, University of Vermont, 2 Colchester Ave., Burlington, VT, 05401, USA; Department of Psychiatry, University of Vermont, 1 S. Prospect St., Burlington, VT, 05401, USA. Electronic address: stacey.sigmon@uvm.edu.
University of Vermont · US

Funding

Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2013 to 2022
$21.3M
TRAINING IN BEHAV. PHARMACOLOGY OF HUMAN DRUG DEPENDENCET32DA007242 · NIDA · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI HEIL, SARAH H, HIGGINS, STEPHEN T · 1990 to 2025
$8.2M
Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluationR01DA042790 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2017 to 2021
$3.0M
Interim Treatment: Leveraging buprenophine + technology to bridge waitlist delaysR34DA037385 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2014 to 2015
$652k
NIDA NIH HHS R01 DA042790NIDA NIH HHS R34 DA037385NIDA NIH HHS T32 DA007242NIGMS NIH HHS P20 GM103644
6 · The paper itself

Abstract

backgroundThe effectiveness of opioid agonist treatment for opioid use disorder (OUD) is well established, and delays to treatment are still common, particularly in rural geographic areas. In a randomized 12-week pilot study, we demonstrated initial efficacy of a technology-assisted Interim Buprenorphine Treatment (IBT) vs. continued waitlist control (WLC) for reducing illicit opioid use and other risk behaviors during waitlist delays. Upon completion of that parent trial, WLC participants were given the opportunity to receive 12 weeks of IBT, permitting an additional within-subject examination of IBT effects.

methodsSixteen WLC participants crossed over to receive IBT, involving buprenorphine maintenance with bi-monthly visits, medication administration at home via a computerized device, daily monitoring calls using an Interactive Voice Response (IVR) phone system, and IVR-generated random call-backs. Biochemically-verified illicit opioid abstinence, changes in psychosocial functioning, and HIV + HCV knowledge were examined among participants originally randomized to the WLC phase and who subsequently crossed over to IBT (IBTc).

resultsParticipants submitted a higher percentage of illicit opioid negative specimens at Weeks 4, 8, and 12 during IBT (75 %, 63 %, and 50 %) vs. WLC (0%, 0%, and 0%), respectively (p's<.01). Participants also demonstrated improvements in anxiety, depression, and HIV and HCV knowledge (p's<.01). Medication administration, daily IVR call and random call-back adherence and treatment satisfaction were also favorable.

conclusionsThis within-subject evaluation provides additional support for interim buprenorphine's efficacy in reducing illicit opioid use and improving health outcomes during waitlist delays for more comprehensive treatment.

Indexed as

AdultAnalgesics, OpioidAnxietyBuprenorphineHumansMaleNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPilot ProjectsRisk-TakingWaiting ListsYoung AdultAnalgesics, OpioidBuprenorphineNarcotic AntagonistsAnxietyBuprenorphineDepressionHepatitisHIVInterim treatmentOpioid agonist treatmentOpioid use disorder

Identifiers

PMID33508690
PMCPMC8148627
OpenAlexW3122597669

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.